Systematic review and Meta-analysis of Gusongbao preparation in treatment of primary osteoporosis.
10.19540/j.cnki.cjcmm.20230130.501
- Author:
Jie-Hang LU
1
;
Zheng-Yan LI
1
;
Guo-Qing DU
1
;
Jun ZHANG
2
;
Yu-Peng WANG
1
;
Jin-Yu SHI
1
;
You-Zhi LIAN
3
;
Fu-Wei PAN
1
;
Zhen-Lin ZHANG
4
;
Hong-Sheng ZHAN
1
Author Information
1. Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine Shanghai 201203, China.
2. Wangjing Hospital, China Academy of Chinese Medical Sciences Beijing 100102, China.
3. Shanghai Baoshan Hospital of Integrated Traditional Chinese and Western Medicine Shanghai 201999, China.
4. Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University Shanghai 200233, China.
- Publication Type:Journal Article
- Keywords:
Gusongbao preparation;
Meta-analysis;
primary osteoporosis;
randomized controlled trial;
systematic review
- MeSH:
Humans;
Bone Density;
Low Back Pain;
Medicine, Chinese Traditional;
Osteoporosis/drug therapy*
- From:
China Journal of Chinese Materia Medica
2023;48(11):3086-3096
- CountryChina
- Language:Chinese
-
Abstract:
This study aims to provide evidence for clinical practice by systematically reviewing the efficacy and safety of Gusongbao preparation in the treatment of primary osteoporosis(POP). The relevant papers were retrieved from four Chinese academic journal databases and four English academic journal databases(from inception to May 31, 2022). The randomized controlled trial(RCT) of Gusongbao preparation in the treatment of POP was included after screening according to the inclusion and exclusion criteria. The quality of articles was evaluated using risk assessment tools, and the extracted data were subjected to Meta-analysis in RevMan 5.3. A total of 657 articles were retrieved, in which 15 articles were included in this study, which involved 16 RCTs. A total of 3 292 patients(1 071 in the observation group and 2 221 in the control group) were included in this study. In the treatment of POP, Gusongbao preparation+conventional treatment was superior to conventional treatment alone in terms of increasing lumbar spine(L2-L4) bone mineral density(MD=0.03, 95%CI[0.02, 0.04], P<0.000 01) and femoral neck bone mineral density, reducing low back pain(MD=-1.69, 95%CI[-2.46,-0.92], P<0.000 1) and improving clinical efficacy(RR=1.36, 95%CI[1.21, 1.53], P<0.000 01). Gusongbao preparation was comparable to similar Chinese patent medicines in terms of improving clinical efficacy(RR=0.95, 95%CI[0.86, 1.04], P=0.23). Gusongbao preparation was inferior to similar Chinese patent medicines in reducing traditional Chinese medicine syndrome scores(MD=1.08, 95%CI[0.44, 1.71], P=0.000 9) and improving Chinese medicine syndrome efficacy(RR=0.89, 95%CI[0.83, 0.95], P=0.000 4). The incidence of adverse reactions of Gusongbao preparation alone or combined with conventio-nal treatment was comparable to that of similar Chinese patent medicines(RR=0.98, 95%CI[0.57, 1.69], P=0.94) or conventio-nal treatment(RR=0.73, 95%CI[0.38, 1.42], P=0.35), and the adverse reactions were mainly gastrointestinal discomforts. According to the available data, Gusongbao preparation combined with conventional treatment is more effective than conventional treatment alone in increasing lumbar spine(L2-L4) bone mineral density and femoral neck bone mineral density, reducing low back pain, and improving clinical efficacy. The adverse reactions of Gusongbao preparation were mainly gastrointestinal discomforts, which were mild.
